Shots:
- The RELIEF study evaluating the efficacy & safety of VYEPTI (100mg, 30-minute IV infusion) vs PBO in a ratio (1:1) in 480 patients with migraine, administered within 1-6 hrs of migraine attack
- The study met its co-primary EPs i.e., median time to headache pain freedom (4 hrs vs 9 hrs) & median time to absence of MBS (2 hrs vs 3 hrs) & 2EPs @ 2hrs post-infusion, demonstrates headache pain freedom (23.5% & 12%), absence of MBS (55.5% & 35.8%), patients required rescue medications (31.5% vs 59.9%) @ 24 hrs treatment
- The exploratory EPs of time to next migraine (10 vs 5 days) and was well-tolerated while safety & tolerability also assessed & compare to safety data from 2 P-III studies, PROMISE 1 & PROMISE 2
Click here to read full press release/ article | Ref: Business Wire | Image: Berlingske
The post Lundbeck Presents Results of Vyepti (eptinezumab-jjmr) in RELIEF Study for Preventive Treatment of Migraine at JAMA first appeared on PharmaShots.
